Clinical Medicine: Therapeutics
Synopsis: An open access, peer reviewed electronic journal that covers therapeutics in human clinical medicine.
Indexing: 2 major databases. Pubmed indexing for NIH-funded research.
Processing time: Decision in 2 weeks for 90% of papers.
Visibility: Accessible to all internet users.
About this journal
Aims and scope:
Clinical Medicine: Therapeutics focuses on the role of therapeutics in human clinical medicine.
Editorial standards and procedures:
Submissions, excluding editorials, letters to the editor and dedications, will be peer reviewed by two reviewers. Reviewers are required to provide fair, balanced and constructive reports.
Under our Fairness in Peer Review Policy authors may appeal against reviewers' recommendations which are ill-founded, unobjective or unfair. Appeals are considered by the Editor in Chief or Associate Editor.
Papers are not sent to peer reviewers following submission of a revised manuscript. Editorial decisions on re-submitted papers are based on the author's response to the initial peer review report.
Indexing:
This journal is indexed by:
- DOAJ
- OAIster
National Institutes of Health Public Access Policy compliant:
As of April 7 2008, the US NIH Public Access Policy requires that all peer reviewed articles resulting from research carried out with NIH funding be deposited in the Pubmed Central archive.
If you are an NIH employee or grantee Libertas Academica will ensure that you comply with the policy by depositing your paper at Pubmed Central on your behalf.
Call for papers:
Read the Editor in Chief's latest call for papers here.
Submission types accepted:
Submissions of the following types of manuscripts are accepted:
- Original research articles.
- Reviews: comprehensive, authoritative, descriptions of any subject within the journal's scope. They may cover basic science and clinical reviews, ethics, pro/con debates, and equipment reviews.
- Commentaries: focused and opinionated articles on any subject within the journal's scope. These articles are usually related to a contemporary issue.
- Hypotheses: articles that present an original hypothesis backed solely by previously published results rather than any new evidence. They should outline significant progress in thinking that would also be testable.
- Letters to the Editor: these can be either a re-analysis of a previously published article, or a response to such a re-analysis from the authors of the original publication.
- Methodology articles: these discuss a new experimental method, test or procedure. The article must describe a demonstrable advance on what is currently available. The method needs to have been well tested and ideally, but not necessarily, used in a way that proves its value.
- Short reports: brief reports of data from original research.
- Meeting reports: a report pertaining to activity at a meeting or conference Articles published in this journal are immediately available without delay upon publication and enjoy substantial visibility.
- Case reports: reports of clinical cases that can be educational, describe a diagnostic or therapeutic dilemma, suggest an association, or present an important adverse reaction. Case reports must meet appropriate ethical standards.
All submissions are subject to prompt, objective and fair peer review in compliance with our Fairness in Peer Review Policy. Copyright in published articles remains with the author(s). Authors are continually informed of the progress of their paper and our staff are friendly and responsive.
One author recently wrote: "I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely."
Criteria for publication:
Publication is dependent on peer reviewers' judgement of papers. Reviewers are asked to provide thoughtful and unbiased feedback to authors to ensure that the conclusions of papers are valid and manuscripts achieve reasonable standards of scholarliness and intelligibility.
Previous work in the field must be acknowledged and papers should read without unreasonable difficulty. Papers should fit comfortably within the scope of the journal.
Reviewers are asked to act in a fair, objective and constructive manner which maintains quality standards and helps authors to communicate their research. They are instructed that in areas of genuinely novel research issues may be raised which cannot immediately be resolved and that absolutely rigorous validation of data may therefore not be possible.
More information on the role of peer reviewers is available on the information for reviewers page. Where authors consider that reviewers have made recommendations which are unreasonable, unobjective or ill-founded they may appeal them to the Editor in Chief or Associate Editor under our Fairness in Peer Review Policy.
Articles submitted to other journals:
We are willing to consider papers which have been peer reviewed by other journals but not accepted for publication.
Services for authors:
Prior to peer review of your paper we can:
- Have your paper's reference style revised to meet our requirements,
- Have your paper's English revised by specialist English-speaking technical editors.
After peer review of your paper we can:
- Have your paper revised in accordance with peer reviewer's recommendations and have a summary of responses to the reviewers created by our specialist external substantive editors,
- Provide bound reprints of your article in colour or black and white ,
- Provide online-early rapid publication if your paper prior to typesetting.
What other authors have said:
Libertas Academica actively requests, receives and acts upon feedback from authors, readers and editorial boards. Here's what some recent authors have said about us:
"Within a couple of days the reviewers had been procured and the manuscript was out."
"The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I've never had such complete communication with a journal."
"LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought."
Article processing fees:
Unsolicitied submissions to this journal are subject to an article processing fee if they are accepted for publication. Article processing fees are used to fund the processing of your paper and development of the journal. Article processing fees are the only compulsory charge you will face and do not vary according to word count, page count, colour figures or any other factor. There is no additional charge for the author(s) to make any use of their article and no charge to readers to access it.
Full fee waivers are available for authors working in undeveloped nations and partial discounts of 20-50% are available to authors in other nations. Authors must be able to verifiably demonstrate their suitability for a discount or waiver. Availability of waivers and discounts is subject to monthly availability and is given at the publisher's discretion. Waivers and discounts must be applied for prior to submission. Neither are available after submission.
Register as a peer reviewer:
Do you wish to register as a peer reviewer? Or are you already a registered peer reviewer but you need to update your contact details? To register or update your details visit the peer reviewer registration form.
Applicants must be able to demonstrate at least five years of continuous experience in the journal's subject area including at least two in the previous 24 months.
Journal newsletter sent to subscribers in week 33, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 32, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 31, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 30, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 29, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 28, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 27, 2009. Register to receive future newsletters.
The Editor in Chief has issued a new call for papers. Read it here.
Journal newsletter sent to subscribers in week 26, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 24, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 23, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 21, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 19, 2009. Register to receive future newsletters.
Follow this journal on Twitter
Journal newsletter sent to subscribers in week 17, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 16, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 15, 2009. Register to receive future newsletters.
This journal has been accepted for indexing in DOAJ.
Journal newsletter sent to subscribers in week 14, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 13, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 10, 2009. Register to receive future newsletters.
New call for papers sent to newsletter subscribers in week 8 2009. Readers who wish to be elligible to receive CFPs should subscribe to the newsletter.
Peer reviewers are sought. Click here to apply or to update your details.
Pharmacotherapy of Paget’s Disease of Bone: Focus on Zoledronic Acid
Konstantinos Tziomalos, Vasilios G. Athyros and Asterios Karagiannis
Second Propedeutic Department of Internal Medicine, Aristotle University, Hippokration Hospital, Thessaloniki, Greece.
Abstract
Paget’s disease of bone (PDB) affects 1%–3% of the population and is associated with increased risk for bone fracture and deformity. Increased osteoclastic activity is the principal characteristic of PDB. Bisphosphonates inhibit osteoclastic activity and represent the mainstay of treatment of PDB. Zoledronic acid, a potent member of this class, normalizes serum alkaline phosphatase (ALP) levels in the majority of patients with PDB and induces sustained disease remissions. It appears to be more effective than both risedronate and pamidronate. However, it is not clear whether bisphosphonates, including zoledronic acid, improve the clinical outcome of patients with PDB. Zoledronic acid was associated with increased risk for atrial fibrillation and osteonecrosis of the jaw in some studies in patients with osteoporosis and cancer, respectively, but not in patients with PDB. Until we have data on the effects of bisphosphonates on clinical outcomes in PDB such as fracture, deformity and osteosarcoma, we must base therapeutic decisions on the data regarding the effects of these agents on disease activity markers (such as serum ALP levels) and bone pain.
Readers of this also read:
- Raltegravir: Its use in the Treatment of HIV Infection
- A Review of Delayed-Release MMX Mesalamine: It’s Use in the Treatment of Ulcerative Colitis
- Pharmacotherapy of Paget’s Disease of Bone: Focus on Zoledronic Acid
- Hypertension: Focus on Olmesartan Medoxomil
- Hypertension: Focus on Olmesartan Medoxomil
- 25/Aug/2009
Antipsychotic Drug Treatment for Patients with Schizophrenia: Theoretical Background, Clinical Considerations and Patient Preferences
- 17/Aug/2009
Benefits of ACE Inhibitors in Diabetes
- 14/Aug/2009
Insomnia: A Review of the Use of Eszopiclone
- 12/Aug/2009
Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib
- 12/Aug/2009
Clopidogrel Bisulfate: A Review of its Use in the Management of Acute Coronary Syndrome
- 07/Aug/2009
A Review of Enteric-coated Mycophenolate Sodium for Renal Transplant Immunosuppression
- 07/Aug/2009
Pharmacotherapy of Epilepsy: Focus on Levetiracetam
- 05/Aug/2009
Current and Prospective Pharmacotherapies in Gastroesophageal Reflux Disease
- 05/Aug/2009
Pharmacotherapy of Candida Infections with Echinocandins
- 04/Aug/2009
Management Options in Chronic Stable Angina Pectoris: Focus on Ranolazine
- 31/Jul/2009
Pharmacotherapy with Pamidronate Disodium of Osteolytic Bone Metastases of Breast Cancer, Osteolytic Lesions of Multiple Myeloma, and Paget’s Disease
- 30/Jul/2009
Pharmacotherapy of Hematologic Malignancies with Tipifarnib
- 29/Jul/2009
Zolmitriptan and the Triptan Era
- 22/Jul/2009
Pharmacotherapy of Complicated Urinary Tract and Intra-abdominal Infections with Doripenem
- 15/Jul/2009
Glimepiride-pioglitazone Hydrochloride in the Treatment of Type 2 Diabetes
- 15/Jul/2009
Safety and Efficacy of the bi-Sulfydryl ACE-Inhibitor Zofenopril in the Management of Cardiovascular Disease
- 15/Jul/2009
Pregabalin and Fibromyalgia Syndrome: A Treatment Option
- 15/Jul/2009
Bevacizumab: Its Place in the Treatment of Advanced Non-small Cell Lung Cancer
- 13/Jul/2009
Safety and Efficacy of Lamotrigine in Older Adults with Epilepsy and Co-Morbid Depressive Symptoms
- 09/Jul/2009
Management of Transfusional Chronic Iron Overload: Focus on Deferasirox
- 09/Jul/2009
Experience with Cinacalcet for Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Stage III and IV
- 09/Jul/2009
Tipranavir: A Review of its Use in Therapy of HIV Infection
- 09/Jul/2009
Single Sevikar®: Combination Therapy for the Treatment of Hypertension
- 01/Jul/2009
Safety and Efficacy of I(131) Tositumomab in the Treatment of non-Hodgkin’s Lymphoma
- 01/Jul/2009
Triptans in the Treatment of Migraine
- 01/Jul/2009
Treatment Options in Smoking Cessation: What Place for Bupropion Sustained-Release?
- 30/Jun/2009
Tetrabenazine in Huntington’s Disease Chorea
- 29/Jun/2009
Pharmacokinetics of Lopinavir in the LPV/R-Meltrex Formulation Compared to the LPV/R-Soft Gelatine Capsule in HIV Infected Patients
- 29/Jun/2009
Pharmacotherapy Update: Hyoscine Butylbromide in the Treatment of Abdominal Spasms
- 23/Jun/2009
Pharmacotherapy Update: Quetiapine use in Bipolar Disorder - What does the evidence tell us?
- 19/Jun/2009
Emerging Therapies for the Treatment of Essential Tremor
- 17/Jun/2009
Safety and Efficacy of Panitumumab in the Treatment of Metastatic Colorectal Cancer
- 12/Jun/2009
Lapatinib in the Treatment of Breast Cancer
- 12/Jun/2009
Secondary Stroke Prevention, and the Role of Antiplatelet Therapies
- 11/Jun/2009
First-line Treatment of Metastatic Breast Cancer: Focus on Bevacizumab
- 10/Jun/2009
A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer
- 08/Jun/2009
Hormone Refractory Prostate Cancer: Focus on Sipuleucel-T
- 08/Jun/2009
Pharmacotherapy of Excessive Sleepiness: Focus on Armodafinil
- 28/May/2009
Safety and Efficacy of Ambrisentan in the Treatment of Pulmonary Arterial Hypertension
- 27/May/2009
Therapeutic Options in Multiple Myeloma: Focus on Bortezomib
- 26/May/2009
A Review of Nelarabine in the Treatment of T-cell Lymphoblastic Leukemia/Lymphoma
- 21/May/2009
A Review of Levofloxacin for the Treatment of Bacterial Infections
- 15/May/2009
Pharmacotherapy of HIV: Focus on Etravirine
- 15/May/2009
The Prevention of Respiratory Syncytial Virus Infection in Children: Focus on Palivizumab
- 14/May/2009
Safety and Efficacy Review of Doxycycline
- 14/May/2009
Pharmacotherapy Update: Fludarabine in the Treatment of Non-Hodgkin’s Lymphoma
- 11/May/2009
A Review of the Pharmacokinetics, Pharmacodynamics and Efficacy of Zolmitriptan in the Acute Abortive Treatment of Migraine
- 11/May/2009
Metastatic Bone Disease in Patients with Solid Tumors—Burden of Bone Disease and the Role of Zoledronic Acid
- 08/May/2009
Lanreotide Autogel® in the Treatment of Acromegaly
- 07/May/2009
Sorafenib in Hepatocellular Carcinoma
- 06/May/2009
Hypertension Management and End Organ Protection: Focus on Aliskiren
- 01/May/2009
Pharmacotherapy of Oral Mucositis with Palifermin
- 01/May/2009
The Rise and Fall of Rosiglitazone
- 30/Apr/2009
Pharmacotherapy of Systemic Sclerosis: focus on Bosentan
- 16/Apr/2009
Efficacy and safety of fixed-dose Lercanidipine-Enalapril for the treatment of hypertension
- 20/Apr/2009
Current Approaches to the Treatment of Gastrointestinal Infections: Focus on Nitazoxanide
- 20/Apr/2009
A Review of Pramlintide in the Management of Diabetes
- 19/Apr/2009
Safety and Efficacy of Pioglitazone/Metformin Combination Therapy in Treatment of Type 2 Diabetes: A Rationale for Earlier Use
- 17/Apr/2009
Pharmacotherapy Options in Atrial Fibrillation: Focus on Vernakalant
- 17/Apr/2009
Pharmacotherapy of Retinal Diseases with Ranibizumab
- 16/Apr/2009
Sitaxentan for the Oral Treatment of Pulmonary Arterial Hypertension: Benefits from Endothelin Receptor Subtype Selectivity?
- 16/Apr/2009
Pharmacotherapy of HIV: A Focus on Atazanavir/Ritonavir a Potent and Convenient Once Daily Ritonavir Boosted Protease-Inhibitor for HIV-1 Infected Adults
- 09/Apr/2009
Hypertension: Focus on Olmesartan Medoxomil
- 08/Apr/2009
Pharmacotherapy of Paget’s Disease of Bone: Focus on Zoledronic Acid
- 08/Apr/2009
A Review of Delayed-Release MMX Mesalamine: It’s Use in the Treatment of Ulcerative Colitis
- 07/Apr/2009
Raltegravir: Its use in the Treatment of HIV Infection
- 03/Apr/2009
Efficacy and Safety of Sitagliptin in the Treatment of Type 2 Diabetes
- 03/Apr/2009
Management of Asthma with ICS and LABAs: different treatment strategies
- 03/Apr/2009
Pharmacotherapy of Insomnia: Focus on Zolpidem Extended Release
- 01/Apr/2009
Safety and efficacy update: alvimopan in postoperative ileus
- 01/Apr/2009
Pharmacotherapy of Chronic Hepatitis B with Entecavir
- 31/Mar/2009
Temsirolimus: a review of its use in the treatment of advanced renal cell carcinoma
- 31/Mar/2009
Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women
- 31/Mar/2009
A review of the use of telbivudine in the treatment of chronic hepatitis B
- 30/Mar/2009
Management of Multiple Myeloma and Myelodysplastic Syndrome: Focus on Lenalidomide
- 30/Mar/2009
Cevimeline for the treatment of dry mouth in patients with Sjogren’s syndrome
- 20/Mar/2009
The Treatment of Ankylosing Spondylitis and Psoriatic Arthritis with Etanercept: A Comprehensive Review
- 09/Mar/2009
Pharmacotherapy of Bipolar I Disorder: Focus on Aripiprazole
- 04/Mar/2009